Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer

Seminars in Radiation Oncology

Volumn 26, Issue 1, 2016, Pages 9-16

  Braunstein, Lior Z ^a   Taghian, Alphonse G ^b  

^a Massachusetts General Hospital ^*  (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER;

BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; DEMOGRAPHY; DNA MICROARRAY; DNA MICROARRAY KIT; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MASTECTOMY; PARTIAL MASTECTOMY; PERSONALIZED MEDICINE; PHENOTYPE; POLYMERASE CHAIN REACTION SYSTEM; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TUMOR VOLUME; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PHENOTYPE; RECEPTORS, ESTROGEN;

EID: 84961859439     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2015.08.002     Document Type: Review

References (51)

1. Wood A.J., Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339(22):1609-1618.
2. Arvold N.D., Taghian A.G., Niemierko A., et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 2011, 29(29):3885-3891.
3. Jansen M.P., Foekens J.A., van Staveren I.L., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005, 23(4):732-740.
4. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358(13):1409-1411.
5. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
6. Ellis M.J., Perou C.M. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013, 3(1):27-34.
7. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
8. Nguyen P.L., Tagian A.G., Katz M.S., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26(14):2373-2378.
9. Wiechmann L., Sampson M., Stempel M., et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 2009, 16(10):2705-2710.
10. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826.
11. Parker J.S., Mullins M., Cheang M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160-1167.
12. Van De Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009.
13. Cronin M., Pho M., Dutta D., et al. Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164(1):35-42.
14. Cobleigh M.A., Tabesh B., Bitterman P., et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005, 11(24):8623-8631.
15. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010, 11(1):55-65.
16. Dowsett M., Cuzick J., Wale C., et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 2010, 28(11):1829-1834.
17. Asad J., Jacobson A.F., Estabrook A., et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?. Am J Surg 2008, 196(4):527-529.
18. Hornberger J., Alvarado M.D., Rebecca C., Gutierrez H.R., Yu T.M., Gradishar W.J. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: A systematic review. J Natl Cancer Inst 2012, 104(14):1068-1079.
19. Ademuyiwa F.O., Miller A., O'Connor T., et al. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 2011, 126(3):797-802.
20. Habel L.A., Shak S., Jacobs M.K., et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006, 8(3):R25.
21. Goldstein L.J., Gray R., Badve S., et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008, 26(25):4063-4071.
22. Badve S.S., Baehner F.L., Gray R.P., et al. Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. JClin Oncol 2008, 26(15):2473-2481.
23. Toi M., Iwata H., Tamanaka T., et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 2010, 116(13):3112-3118.
24. Mamounas E.P., Tang G., Fisher B., et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010, 28(10):1677-1683.
25. Geary M. Abstracts of the Society of Surgical Oncology 66th Annual Cancer Symposium. National Harbor, Maryland, USA. March 6-9, 2013. Ann Surg Oncol 2013, 20(1):S6-164. (Suppl 1).
26. Solin L.J., Gray R., Baehner F.L., et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013, 105(10):701-710.
27. Van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
28. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874.
29. Sørlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100(14):8418-8423.
30. Geiss G.K., Bumgarner R.E., Birditt B., et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008, 26(3):317-325.
31. Gnant M., Filipits M., Greil R., et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014, 25(2):339-345.
32. Dowsett M., Sestak I., Lopez-Knowles E., et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013, 31(22):2783-2790.
33. Fitzal F., Filipits M., Fesl C. Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients. J Clin Oncol 2014, 32.
34. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98(17):1183-1192.
35. Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: A prospective community-based feasibility study (RASTER). Lancet Oncol 2007, 8(12):1079-1087.
36. Wittner B.S., Sgroi D.C., Ryan P.D., et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 2008, 14(10):2988-2993.
37. Mook S., Schmidt M.K., Viale G., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009, 116(2):295-302.
38. ®) among breast cancer patients with 4-9 positive lymph nodes. Breast 2013, 22(5):682-690.
39. Kok M.d., Koornstra R., Mook S., et al. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. Breast 2012, 21(6):769-778.
40. Glück S., de Snoo F., Peeters J., Stork-Sloots L., Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 2013, 139(3):759-767.
41. Straver M.E., Glas A.M., Hannemann J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119(3):551-558.
42. Knauer M., Cardoso F., Wesseling J., et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 2010, 103(12):1788-1793.
43. Tramm T., Mohammed H., Myhre S., et al. Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: A study of gene expression in the DBCG82bc cohort. Clin Cancer Res 2014, 20(20):5272-5280.
44. Speers C., Zhao S., Liu M., Bartelink H., Pierce L.J., Feng F.Y. Development and validation of a novel radiosensitivity signature in human breast cancer. Clin Cancer Res 2015, 21(16):3667-3677.
45. Torres-Roca J.F., F.W., Caudell J.J., et al. Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer. Int J Radiat Oncol Biol Phys 2015, 93(3):631-638.
46. Eschrich S.A., Pramana J., Zhang H., et al. A gene expression model of intrinsic tumor radiosensitivity: Prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 2009, 75(2):489-496.
47. Eschrich S., Zhang H., Zhao H., et al. Systems biology modeling of the radiation sensitivity network: A biomarker discovery platform. Int J Radiat Oncol Biol Phys 2009, 75(2):497-505.
48. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002, 347(16):1233-1241.
49. Fyles A.W., McCready D.R., Manchul L.A., et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004, 351(10):963-970.
50. Early Breast Cancer Trialists[U+05F3] Collaborative Group, Darby S., McGale P., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011, 378(9804):1707-1716.
51. Hughes K.S., Schnaper L.A., Bellon J.R., et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J Clin Oncol 2013, 31(19):2382-2387.